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Background: Pandemic type A (H1N1) influenza arose in early 2009, probably in Mexico and the United States, and
reappeared in North America in September for seven more months. An amino acid substitution in the
hemagglutinin (HA), D222G, has been reported in a significant proportion of patients with a severe and fatal
outcome. We studied the prevalence of HA222 substitutions in patients in Mexico during the second wave and its
association with clinical outcome and pathogenicity in a mouse model.
Methods: The nucleotide sequences of hemagglutinin (HA) from viruses collected from 77 patients were
determined including 50 severe and fatal cases and 27 ambulatory cases. Deep sequencing was done on 5 samples
from severe or fatal cases in order to determine the quasispecies proportion. Weight loss and mortality due to
infection with cultured influenza viruses were analyzed in a mouse model.
Results: Viruses from 14 out of 50 hospitalized patients (28%) had a non aspartic acid residue at the HA 222
position (nD222), while all 27 ambulatory patients had D222 (p = 0.0014). G222 was detected as sole species or in
coexistence with N222 and D222 in 12 patients with severe disease including 8 who died. N222 in coexistence with
D222 was detected in 1 patient who died and co-occurrence of A222 and V222, together with D222, was detected
in another patient who died. The patients with a nD222 residue had higher mortality (71.4%), compared to the
group with only D222 (22.2%, p = 0.0008). Four of the 14 viruses from hospitalized patients were cultured and
intranasally infected into mice. Two viruses with G222 were lethal while a third virus, with G222, caused only mild
illness in mice similar to the fourth virus that contained D222.
Conclusions: We confirm the elevated incidence of HA222 (H1N1)pdm09 variants in severe disease and mortality.
Both clinical and mouse infection data support the idea that nD222 mutations contribute to increased severity of
disease but additional determinants in disease outcome may be present.* Correspondence: gustavo.reyesteran@gmail.com
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Table 1 Pandemic influenza A (H1N1) viruses
characterized by Sanger sequencing for amino acid










222D (wt) 100% (27) 84.6% (22) 58.2% (14)
222D, 222E, 222G, 222N 0% (0) 7.7% (2) 8.4% (2)
222G 0% (0) 0% (0) 12.5% (3)
222D, 222G 0% (0) 7.7% (2) 12.5% (3)
222D, 222N 0% (0) 0% (0) 4.2% (1)
222D, 222V, 222A 0% (0) 0% (0) 4.2% (1)
All 222 variants 0% (0) 15.4% (4) 41.8% (10)
Clinical outcome based on patient information, assigned into categories by a
medical specialist according to WHO guidance criteria.
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The first pandemic of this century originated as a novel
influenza A/H1N1 virus (pdm09) in 2009. This virus was
first detected in March and April in California and sev-
eral cities of Mexico [1,2]. A second wave included those
cases occurring from late August 2009 and March 2010
[3]. As of August 2010, more than 214 countries had
reported laboratory confirmed cases of pdm09, including
over 18,449 deaths [4]. Although most confirmed cases
resulted in uncomplicated influenza illness, some pa-
tients required hospitalization due to severe pneumonia
and respiratory failure, with a fatal outcome in some
cases [5]. The factors that control the generation of
pathogenicity in this novel influenza virus remain un-
known. However the ability of influenza viruses to acti-
vate innate immunity [6], induce apoptosis mediated by
the PB1-F2 protein [7], and contributions of the viral
RNA polymerase proteins [8], the NS1 and M2 proteins
[9,10], and viral receptor binding preference [11] could
be important. The tissue tropism and the binding of
influenza viruses to their target cells is mediated by
the viral HA protein which recognizes cell surface
glycoconjugate receptors that terminate in sialic acid
(SA) residues. It has been described that single amino
acid changes can alter receptor specificities, and amino
acid changes in HA D222G have been associated with
acquisition of affinity for N-acetylneuraminic acid with
an α-2,3 ketosidic linkage to galactose (SA α2,3Gal), in-
creasing the infection of lower respiratory cells and like-
lihood of viral pathogenicity [12].
HA D222G substitution or different variants (D222N,
D222S) has been observed in pdm09 viruses isolated
from fatal and mild cases in several countries [13,14].
The first report of substitutions for D222 showed con-
siderable frequency of change at this position (18%) only
in fatal and severe cases in Norway [15]. In contrast, two
later studies found D222G substitution in mild cases, with
Hong Kong and Greece reporting 4% and 15%, respect-
ively [16,17]. The effect of these substitutions on viral
pathogenicity in animal models is also unclear. In the
most recent report [18] a recombinant pdm09 with the
D222G substitution showed increased virulence in mouse
model but was not lethal in the mouse or ferret model.
In the present work we describe a high prevalence
(28%) of the D222G substitution in coexistence with
D222N and D222S in 50 pdm09 positive patients admit-
ted through the emergency room at the National Insti-
tute of Respiratory Diseases in Mexico City during the
second pandemic wave. Viruses containing mutations in
HA position 222 were associated with higher mortality.
In addition, two of three isolated viruses with mutations
in this position were lethal in mice. Substitutions at
D222 might be associated with increased pathogenicity
in humans and also in mice, but the current resultssuggest that additional unknown determinants also con-
tribute to pathogenicity.
Results
Detection of variants in HA 222 position in severe and
fatal cases
The sequences obtained by the Sanger method from
three or four different amplifications of each sample of
the partial HA gene indicated that 14 out of 50
hospitalized patients (28%) had a non aspartic acid resi-
due at the HA 222 position (GenBank number accession
CY100425-CY100438), while none of 27 outpatients had
a substitution at this position. The rate of non aspartic
acid HA 222 residues for hospitalized vs. ambulatory
patients was significantly higher (p = 0.0014). Four
samples had a RRT codon (patients INER014, INER047,
INER068 and INER405), assuming R is the ambiguity
code for A and G, meaning that these viruses could have
AAT (N), AGT (S), GGT (G) or GAT (D) at this pos-
ition. Next generation sequencing was done for samples
INER047 and INER405 and the quasispecies proportion
was determined (see data below). Five samples had wild-
type D222 coexisting with G222 (INER088, INER111,
INER264, INER307 and INER426), 3 had only a G222
substitution (INER114, INER147, INER306), 1 sample
had wild type D222 coexisting with N222 (INER399)
and finally 1 sample had wild type D222 coexisting with
V222 and A222 (INER057) (Table 1). Of the 24 fatal
cases, 10 presented a mutation in HA amino acid pos-
ition 222. G222 was detected as sole variant or as a co-
variant at position 222 in 8 patients. N222 was detected
in 1 patient who died and the variants V222 and A222
were also detected in 1 patient.
Clinical characteristics of hospitalized patients
When considering respiratory illness during an outbreak
as our study population, and separating hospitalized
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tory patients as mild cases, we found that the proportion
of the D222G mutation was significantly higher in the
former group (14 of 50, 28%) than in the ambulatory
patients (0%, p = 0.001, Table 1). Within the hospitalized
patients, the mortality of the patients, which were cases
with the mutation, was significantly higher than the
patients without (p = 0.0008).
Additionally there was a significantly higher use of
mechanical ventilation in the patients with a non D222
residue (p < 0.0001) when comparing with hospitalized
patients with D222 only (0.0197). Overall, 41.7% of
patients that died and 37.5% of patients that required
mechanical ventilation presented variants in residue 222,
whereas only 7.5% of the survivors and 4.5% of the
patients that did not require mechanical ventilation had
these variants.
Clinical characteristics of the patients are shown in
Table 2. There were no significant differences in demo-
graphics such as age, gender or body mass index. The
clinical presentation was worse in patients with variants in
the HA 222 position, exhibiting greater neutropenia and
lymphopenia (Table 2). All hospitalized patients suffered
from multifocal pneumonia. Among other co-morbidities
analyzed, patients with non D222 variant viruses had
higher systemic arterial hypertension when compared to
patients with only D222 virus (p = 0.0278) (Table 2). The
time from onset of symptoms to hospitalization were simi-
lar in both groups (Table 2).
To determine if D222 variants emerged in patients
with longer evolution time, we analyzed the days from
onset of symptoms to sample time at the hospital admit-
tance and the presence or absence of D222 variants.
There was no statistical difference (p = 0.4055) between
patients with variants in the 222 position and patients
without these substitutions (Figure 1).
Genetic variations at positions 715–716 of HA nucleotide
sequences
To determine the genetic variations at nucleotide posi-
tions 715–716 of the HA open reading frame (ORF)
coding for amino acid 222 and to analyze the complete se-
quence of some influenza viruses with these variants, two
different strategies of next generation sequencing were
used. We performed sequencing using HA amplicons of
sample INER405. The GS Sequencer FLX Titanium
platform produced 33,807 reads from a cDNA library
generated from the clinical specimen, of which 3,870 were
viral sequences after the reads were filtered for human
sequences. To identify heterogeneous populations, the se-
quencing reads of HA were mapped against an influenza
reference sequence using GS Reference Mapper (Figure 2).
At codon 222 we found 29% of GAT, 38.2% of GGT, 29%
AAT and one read had an undefined codon.The whole genome of four influenza viruses was also
determined by Illumina Genome Analyzer IIx for viruses
isolated from patients with a severe and fatal outcome,
and whose variants at nucleotide position 715–716 had pre-
viously been determined by Sanger sequencing (INER047,
INER264, INER306 and INER307, GeneBank number ac-
cession CY100461-CY10068, CY100519-CY100542). With
this strategy, 3.8 ×106 to 8 ×106 total reads per sample
were obtained, of which 1.7 ×106 to 4.6 ×106 reads
corresponded to the influenza reference genome. The
codon at position 222 of HA of INER047 had 5% GAT
(D), 32.5% GGT (G) and 62.5% AAT (N). Sample
INER306 had 93% GAT (D) and only a few reads of GGT
(G) and AAT (N) in the codon for residue 222. These
findings were in agreement with the Sanger sequencing
in samples INER047 and INER405; however three
samples (INER264, INER306 and INER307) were found
to contain >93% of the triplet GAT (D) by metagenomic
analysis.
Detection of other polymorphisms in influenza viruses of
severe and fatal cases
In order to detect other mutations that could determine
pathogenicity of these isolates we analyzed the entire
genome of 5 samples (INER047, INER264, INER306,
INER307 and INER405) that were isolated from patients
with severe or fatal outcome. Several non-synonymous
substitutions as compared to A/California/04/2009
(H1N1) (accession number GQ280797.1) were detected
in every segment (Table 3). Seventeen substitutions were
observed in three or more samples. Some of these
substitutions (G172R and A203T in HA, L95P and
V180I in NS1, Q7R and L106F in NS2, V106I and
T381N in NA, P224S in PA and Q194H in PB1) were
reported in GenBank for only a small number of pdm09
from Mexico and the United States. G172R presented
polymorphisms in samples INER047, INER264 and
INER306. HA codon 172 of sample INER047 had 78% of
GGA (G) and 22% AGA (R), INER264 had 43% GGA
(G) and 57% AGA (R), while INER306 showed 75%
GGA (G) and 25% AGA (R). None of the viruses
described in the present study had the amino acid
change from histidine to tyrosine at residue 274 of the
NA, associated with resistance to oseltamivir.
Pathogenesis of HA 222 variants in mice
All 14 clinical specimens from hospitalized patients were
placed in MDCK cell culture in an attempt to derive a
stock of virus from each. Four of the viruses (INER047,
INER111, INER307 and INER405) were successfully
cultured and a stock of virus was generated and titered
on MDCK cells. Analysis of the viral variants in each
stock from 20 different plaques of each showed that two
of four isolates (INER111 and INER405) had only glycine
Table 2 Clinical characteristics of hospitalized patients and co morbidities identified in hospitalized patients
Variable 222D 222G/N/V/A p
Female gender 33.33% 66.67% 0.0884
Age (yrs) 40.5 (26–50.5) 39.5 (29.5 - 47.5) 0.9145
BMI 30.57 (26.93 - 33.06) 35.77 (27.69 - 38.02) 0.359
Evolution time (days) 7 (4–8) 4.5 (4–6.5) 0.2102
Heart rate (bpm) 110 (84.5 - 120) 108 (90.5 - 117.5) 0.8702
Resp Rate 28 (22–32) 24 (22–28) 0.1951
O2 saturation (skin) 83 (64.5 - 87) 70 (60–78.5) 0.0793
O2 saturation (blood) 84 (68.9 - 88.6) 73.35 (67.6 - 82.6) 0.168
fiO2 21 (21–28) 21 (21–76.25) 0.1668
Kirby score 192.14 (116.71 - 235.72) 170.95 (73.5 - 216.43) 0.2
APACHE II 9 (7–12) 8 (6.25 - 11) 0.6787
SOFA score 4 (2–7) 4 (3.25 - 6) 0.6646
Alkaline phosphatase 105 (78.25 - 136.75) 94 (87.5 - 157.5) 0.5886
Platelets 183500 (128500–236500) 130500 (107000–176500) 0.1275
Albumin 3.4 (3–3.87) 2.9 (2.48 - 3.44) 0.0509
Leukocyte count 6800 (4650–9150) 4450 (3300–5050) 0.0079*
Neutrophyl count 5750 (3700–8460) 3550 (2700–4300) 0.0079*
lymphocyte count 795 (500–1050) 400 (300–500) 0.031*
Hemoglobin 15.25 (13.3 - 15.85) 12.65 (10.75 - 13.35) 0.0017*
Co morbidities 222D 222G/N/V/A p
Obesity 13.89% 8.33% 0.9999
Diabetes mellitus 40.5 (26–50.5) 39.5 (29.5 - 47.5) 0.9145
Systemic arterial hypertension 5.56% 33.33% 0.0278*
Asthma 11.11% 0% 0.5597
Pseudomonas Sp. 8.33% 0% 0.5629
Staphylococcus Sp 11.11% 8.33% 0.9999
Other Acinetobacter baumannii, Klepsiella pneumonie, HIV (2), COPD,
pulmonary fibrosis, unspecified mycobacteria
Down syndrome
Values are medians (interquartile range).
* statistically significant.
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with glycine and one virus with asparagine. All viruses of
sample INER307 had D222. The HA sequencing data
suggests that culturing of the clinical isolates on MDCK
cells tended to preferentially select one of the variants
from each that had been identified in the analysis of
HA quasispecies variability in the original clinical
isolates. Complete sequencing of all other genes from
the INER307, INER405 and INER047 MDCK-grown
virus stock (GeneBank number accession KC261306-
KC261337) indicated no changes associated with adapta-
tion to cell culture compared to the sequences obtained
from the clinical isolates (data not shown). The complete
sequence of the MDCK-grown virus INER111 was also
determined but the sequence of the clinical isolate was
not available for comparison.As all four of the virus stocks had been derived from
patients that had required hospitalization due to the sever-
ity of their illness, it was of interest to analyze the patho-
genicity of infection with each virus in a mammalian
animal model of infection. Intranasal infection of mice
with each revealed differential pathogenesis; INER047 and
INER111 viruses were lethal with rapid weight loss. Mice
infected with viruses INER047 died at 4–6 days post-
infection (dpi), whereas mice infected with virus INER111
died at 4 and 5 dpi (Figure 3A). INER047 was isolated
from a patient that died and INER111 was from a patient
requiring mechanical ventilation and extended hospi-
talization. Mice infected with all of the viruses lost ≥ 18%
body weight, however mice infected with viruses INER307
and INER405 recovered the body weight by 13 dpi
(Figure 3B). The 50% mouse lethal dose (MLD50) for
Figure 1 Time from onset of symptoms to sample time at the
hospital, for patients with and without the D222 variants. WT:
wild type (222D). There were no statistical differences (p = 0.4055).
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(expressed as the log10 of the 50% tissue culture infectious
dose) respectively, whereas INER307 and INER405 were
not lethal even at the highest doses used for infection
(maximal dose of 6.5 TCID50). All of the viruses replicated
efficiently in mouse lungs and high titers persisted until at
least 5 dpi. The titers associated with viruses INER047
and INER111 causing lethal infection tended to be higher
on both days than titers induced by viruses INER307 and
INER405 that were not lethal (Figure 3C).
Mouse pathology
All of the viruses replicated efficiently in mouse lungs
and high titers persisted at least until day 5 PI. The titersFigure 2 D222 variants obtained by deep sequencing of sample 405.
(N1 position), arrows indicate both positions of the HA sequence, and the
type GAT (D), in pink AAT (N), in green GGT (G) and in black undefined codassociated with viruses INER047 and INER111 causing
lethal infection tended to be higher on both days than
titers induced by viruses INER307 and INER405 that
were not lethal (Figure 3C). Lesions in lungs of animals
infected with strains INER307 and INER405 were similar
and were primarily limited to the bronchioles. However,
in addition to the presence of bronchiolar lesions, lungs
from animals infected with strains INER111 and
INER047 showed a diffuse pneumonitis involving most
of the examined lung tissue. At 3 dpi, lesions were most
often limited to the bronchioles with only scattered
involvement of the alveolar walls (data not shown).
Although there was still some ongoing necrosis of
bronchioles at 5 dpi, many bronchioles showed epithelial
hyperplasia typical of a regenerative process (Figure 4A
and Figure 4B). Lesions observed in animals infected
with strain INER111, at both 3 and 5 dpi, showed a
more severe necrotizing bronchiolitis with many
bronchioles showing complete loss of epithelium. In
addition, there was a diffuse pneumonitis char-
acterized by expansion of alveolar walls by inflamma-
tory cells and edema with multifocal areas of necrosis
(Figure 4C). At 5 dpi in lungs of animals infected
with strain INER047, in addition to the pneumonitis
observed at 3 dpi (data not shown) approximately
50% of the section was consolidated and lung tissue was
almost completely replaced by neutrophils (Figure 4D).
Lesions were not observed in non-infected control
animals (Figure 4E).Schematic representation of two nucleotide variations, 715 and 716
alignment image of the 100-mer reads. Every read shown in blue wild
on. Reference sequence was A/Mexico/InDRE4487/2009(H1N1).
Table 3 Non-synonymous substitutions* detected in 5
samples with 222 variants (INER047, INER264, INER306,
INER307 and INER405)
Gene Substitution Subject:
INER047 INER306 INER405 INER264 INER307
PB1 V587G X X X X
A652V X X X X X
PB2 E191G X
Q194H X X X X X






NP S69P X X
V100I X X X X X
T373I X
NA V106I X X X X X
N248D X X
V304A X




NS2 Q20R X X X X
L58F X
L120F X X X X
NS1 V65M X
L95P X X X X
I123V X X X X X
I128T X




N48D X X X
V169I X
G172R X X X
S179N X X X
W194R X
A203T X X X X
T214A X X X X X
I338V X X X X X
Y528C X
* Sequences used for comparison were from Influenza A virus (A/California/04/
2009(H1N1)) accession number GQ280797.1.
** HA positions are given without removing the signal peptide.
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viral antigen (nucleoprotein; NP), an extensive distribu-
tion was found in bronchioles and only occasionally in
macrophages and pneumocytes within alveolar walls of
lungs from animals infected with strain INER405
(Figure 5A) similar to that observed for INER307 (data
not shown). For strains INER047 and INER111 viral
antigen was detected in bronchiolar epithelium as well
as extensively within alveolar macrophages, necrotic
debris within alveolar spaces and within pneumocytes
(Figure 5B). Within areas of consolidation, antigen could
be detected in numerous cells with the morphological
appearance of macrophages or pneumocytes (Figure 5C).
Viral antigen (NP) was not observed in non-infected
control animals (Figure 5D).
Discussion
D222G is the main substitution found in reports
associated with severe or fatal cases of pdm09 [15,19].
Here we found this substitution only in viruses isolated
from severe cases; we also found a correlation between
the risk of death and HA 222 variants. Low white blood
cell (WBC) levels and low hemoglobin levels correlated
with the presence of HA 222 variants, and suggested
that the viruses harboring variants in HA 222 could be
associated with a more severe respiratory disease. Not
all severe or fatal cases had this mutation but its emer-
gence could intensify the severity of the disease.
A recent study found a delayed clearance of virus in
patients with severe disease [20], which may represent an
opportunity for the accumulation of different variants (in-
cluding D222G) in patients. However in this study we
found no correlation between duration of disease and
emergence of D222 variants, supporting the argument that
the substitutions appeared spontaneously and sporadically.
Respiratory tract cells expressing α2,3 receptors are
more abundant deeper in the human airway, an observa-
tion that has led to the hypothesis that viruses with dual
receptor specificity can replicate to higher titers in lungs,
resulting in a more severe course of disease [11]. Recent
studies suggest an increased receptor affinity of the
222G variant for ciliated bronchial epithelial cells, which
may have an impact on disease severity [21]. Some stud-
ies indicate that such variants were also found more
frequently in specimens obtained from the lower respira-
tory tract than from the nasopharynx [19]. Our findings
indicate that the 222 variants including G222, N222,
V222 or A222 were present in nasopharynx, showing
their presence in the upper respiratory tract. Consistent
with the presence of these variants in the upper respira-
tory tract, transmission of influenza virus with D222G
from a patient with severe disease to a family member
has been reported [22]. Other studies found that virus
with D222G had acquired the ability to bind to
Figure 3 (See legend on next page.)
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Figure 3 Pathogenicity of pdm09 isolates in mice. A) Cumulative survival curves in mice after intranasal inoculation with different viruses
isolated from hospitalized patients are shown. Three mice per group were inoculated with different viruses: INER307 (D222), INER047 (G222:N222,
19:1), INER111 (G222) and INER405 (G222). Mice were monitored for 14 days. B) Mean body weight and observations in mice infected intranasally
with 5.5 TCID 50 of viruses isolated from hospitalized patients. Body weight losses were determined daily up to day 14 after inoculation. C) Viral
titer were determined by TCID50 in lung homogenates of mice infected by viruses from the hospitalized patients.
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preferential receptor of human viruses that is associated
with attachment to cells of the upper respiratory tract
[23]. Viruses with G222 do have dual tropism, perhaps
resulting in more efficient infection of the lower respira-
tory tract, causing more severe disease. D222G, D222N,
and D222E changes have been found in viruses isolated
in different countries [15,19,22,24], but the D222V
amino acid change has not been previously reported. A
sequence of HA with A222 has been submitted to
GenBank, but without any published clinical data.
Changes in HA amino acid position 222 located in the
receptor-binding cavity might potentially influenceFigure 4 Lung pathology of mice infected with various strains of H1N
showing that lesions are limited to bronchioles with necrosis, epithelial hyp
cells (arrow). H&E stain. B. Lung from an animal infected with strain INER40
involvement (arrow). H&E stain. C. Lung from an animal infected with strain
walls. Note small area of consolidation with neutrophilic infiltrate (arrow). H
large areas of consolidation due to neutrophilic infiltrate (*). H&E stain. E. Lreceptor binding of the influenza virus. Changing an
acidic and polar amino acid (D) to neutral and non-
polar (G, V and A) residue could affect the tropism of
these new variants. Detection of HA 222 variants has been
realized using both pyrosequencing and Sanger methods,
resulting in different proportion of polymorphisms in
that position [25], in our case we found discrepancies also
between both methodologies, due perhaps an enrich-
ment of minority population during PCR used to amplify
metagenomic sequencing library, especially given low
amount of RNA used.
We also found that HA substitution G172R, which co-
segregated with HA amino acid 222 variants, was1 at 5 dpi. A. Lung from an animal infected with strain INER307
erplasia and peribronchiolar infiltrates of lymphocytes and plasma
5 shows bronchiolitis (arrowhead) and small areas of alveolar
INER111 showing widespread inflammation and necrosis of alveolar
&E stain. D. Lung from an animal infected with strain INER047 showing
ung from a non-infected control animal. H&E stain. Bar = 100 μm.
Figure 5 Immunohistochemical detection of influenza A specific antigen (NP) in mice infected with various strains of H1N1 at 5 dpi.
A. Lung from an animal infected with strain INER405 (also representative of INER307 infection) showing detection of viral antigen in bronchiolar
epithelial cells (arrowhead) and occasionally in cells within alveolar walls (arrows). Bar = 50μm B. Lung from an animal infected with strain
INER111 showing viral antigen within bronchiolar epithelium (arrowhead) as well as extensively within alveolar walls (arrows). Bar = 50μm C. Viral
antigen could be detected extensively throughout areas of consolidation (arrows) in an animal infected with strain INER047. Bar = 50 μm. D.
Immunohistochemistry for influenza A specific antigen (NP) on lung from a non-infected control animal. Bar = 100μm.
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the HA antigenic site Sa that could be implicated in
antigenic changes of HA [26]. In fact, future amino acid
substitutions in the antigenic sites of pdm09 HA
(Gly172Glu) have been anticipated [26]. Furthermore, a
HA variant with G172E was found in one fatal case [27].
The biological significance of the presence of both
substitutions and their relationship with severity remains
unknown.
The severity of the disease observed in human patients
was generally consistent with the disease observed in
mice. The virus INER047 isolated from a patient with a
fatal outcome was lethal at 4 to 6 days PI in mice; and
the virus INER111 that caused severe disease in a patient
requiring mechanical ventilation was also lethal in mice
at 4 and 5 days PI. However, the virus INER405 that had
222G in HA was of limited pathogenicity in mice. This
virus was isolated from a patient who recovered after
being hospitalized for one month showing an association
between the virus and severe infection. However, the
mouse study results suggest that additional determinants
of pathogenicity in mammals likely exist, aside from
222G in HA, that might be responsible for severe disease
in humans but are not determinants of disease in mice.
This data suggests that there might be pathogenic
factors affecting the clinical course of the disease in
humans that have not been described. A recent report in
an animal model showed that a pdm09 D222G virus
caused more severe disease with fatal outcome in mice,compared with the wild type influenza virus [23,28], al-
though experiments with ferrets did not support a causal
link of D222G substitution with virulence [18].
Here we report a high prevalence of pdm09 HA codon
222 variants in severe and fatal cases of pneumonia in
Mexico City during the second wave of the 2009 influ-
enza pandemic. Recent data confirmed an increase in
the overall mortality in Mexico during the pandemic and
also mortality due to respiratory and cardiovascular
causes, especially in young and middle age individuals
[29]. Our results support the suggestion that substitution
at HA position 222 is associated with pdm09 pathogen-
icity, with variants appearing spontaneously during the
two pandemic waves in Mexico. Some reports and se-
quence data have demonstrated that 222 variants
appeared in the early phases of the pandemic, increased
during 2009–2010 influenza season and have reduced to
their present levels during 2010–2011 and 2011–2012
influenza season [30,31]. Bacterial infection or coexisting
conditions do not appear to be major contributing
factors to the severity (Table 2). We have identified add-
itional viruses with 222 variants (D222V and D222A) in
the same individual, but the biological importance of
these substitutions in tropism and pathogenicity remains
to be elucidated. The disease observed in animal models
was generally concordant with the clinical outcome of
patients, but additional determinants of virulence may
contribute to the increased severity of disease observed
in mammals and is a significant point for further
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Material and methods
Patients
Respiratory samples were obtained from all patients who
were hospitalized at the National Institute of Respiratory
Diseases in Mexico City, during September 2009 to April
2010. Twenty-seven patients that sought medical care at
our institution during the same period of time, but that
did not require hospitalization were also included. Naso-
pharyngeal swabs were collected and infection by pdm09
was assessed by a real-timereverse-transcriptase–polymer-
ase-chain-reaction (RT-PCR). This study was approved by
the Bioethics and Research Committee of the National
Institute of Respiratory Diseases in Mexico (B-0411).
Written informed consent was provided by study
participants and/or their legal guardians.
Sanger sequencing of HA
Viral RNA was extracted from 200 μL of respiratory
samples using a high throughput system (MagNA PureW,
Roche, Indianapolis, IN, USA). RT-PCR was performed
with the one-step RT-PCR kit (QIAGEN, Valencia, CA,
USA). The HA gene was partially sequenced; briefly, the
initial amplifications were performed using specific
primers for pdm09: HA 58F 50 TTATGTATAGGTTAT
CATGCGAA 30 and HA 1676R 50 ACCCATTAGAGCA
CATCCAGAAAC 30, a second round PCR reaction were
performed with HA 149F 50 TAGAAGACAAGCATAA
CGGGAAA 30 and HA 865R 50 CTGGTGTATCTGA
AATGATAATA 30 (608 bp). Nucleotide sequences of
PCR products were determined using BigDyeW Termin-
ator cycle sequencing kit (Applied Biosystems, Foster
City, CA, USA) and were analyzed with the ABI Prism
3100 analyzer sequencer (Applied Biosystems). Nucleo-
tide sequences of PCR products were aligned and
analyzed using Clustal X and MEGA 4.0 respectively.
Illumina next generation sequencing and sequence
analysis
Whole genome of influenza A isolates was amplified in
an one tube multisegment RT-PCR reaction as previ-
ously reported [32]. Products obtained were purified and
concentrated and used as input material in constructing
multiplex libraries using Illuminas Genomic DNA
sample Prep Kit with multiplexing primers. Three hun-
dred base-pair sized libraries were loaded in a flow cell
(four libraries per lane) from a Genome Analyzer IIx
(Illumina, San Diego, CA). Sequencing was performed
through 46 cycles of single base pair extensions,
followed by acquisition of multiplex code. Image analysis
was done using goat.py, and the base calling was done
using Bustard.pl, both programs included in Off-LineBasecaller Software v1.6 (Illumina, Hayward, CA).
Processing of sequence data was carried out using Maq
version 0.7.1 [27] and R/Bioconductor [33] programs. All
reads were quality filtered using the Off-Line basecaller
Software v1.6 (Illumina, San Diego, CA). Reads were
aligned to reference influenza A genome A/Netherlands/
602/2009, with maximum of 5 mismatches allowed.
GS Sequencer FLX Titanium platform
For sample INER405, the HA gene was amplified using a
pair of specific primers: MBTuni12, HAREV1166 (50
GGCATTCTGTGTGCTCTTCA 30) and MBTuni13,
HAFW756 (5’ AGCCGGGAGACAAAATAACA 3’). A
single stranded DNA library was prepared with the GS
Titanium General Library Preparation kit (Roche) as
specified by the manufacturer. The DNA library was
clonally amplified by emulsion PCR (emPCR) with the
GS Titanium emPCR kit (Roche). The amplified beads
were recovered and enriched and approximately 340,000
beads were loaded on one line and sequenced in the
PicoTiterPlate using a GS Titanium Sequencing reagents
kit XLR70. All sequencing reads, were assembled separ-
ately in GS De novo Assembler Version 2.0.00. The
resulting contigs were analyzed using NCBI megablast
program, mapping against an influenza reference se-
quence (A/Mexico/InDRE4487/2009(H1N1)).
Mouse study
Influenza viruses were isolated from respiratory samples
in MDCK cells (ATCC # CCL-34). Titers of each stock
virus were determined as the 50% tissue culture infec-
tious dose (TCID50) and reported as the log10 of the
TCID50 value. Each of the viruses was plaqued on
MDCK cells and 20 plaques of each were picked and
stocks were produced in MDCK cells. Viral RNA was
isolated from each plaque virus stock and the HA
sequenced in the region of amino acid 222. To deter-
mine the 50% mouse lethal dose (MLD50), serial 10-fold
dilutions of each virus, starting at 6.5 TCID50,
were intranasally (i.n.) inoculated in 3 anesthetized
(isoflurane) mice/dilution. The MLD50 was expressed as
the log10 of the TCID50. Calculations for TCID50 and
MLD50 were done according to the method of Reed and
Muench [34].
Groups of twelve 5-6-week-old female BALB/c mice
(Charles River) were infected i.n. with 5.5 TCID50 of
each virus. Animals were weighed daily for 14 days and
monitored for clinical signs. Three mice per group were
sacrificed on days 3 and 6 post-infection and lungs were
removed aseptically. For determination of viral titers,
lung tissues were harvested, weighed, homogenized and
supernatants were titrated in 10-fold serial dilutions on
MDCK cells. Titers were expressed as log10(TCID50) per
gram of tissue.
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Lung samples were fixed in 10% neutral buffered forma-
lin, embedded in paraffin, sectioned at 5 μm and stained
with haematoxylin and eosin for examination by light
microscopy. For immunohistochemistry, paraffin tissue
sections were quenched for 10 minutes in aqueous 3%
H2O2 then pretreated with proteinase K for 15 minutes.
Slides were blocked for 30 minutes with Rodent Block
M from MM horse radish peroxidase (HRP)-polymer kit
(Biocare Medical, USA) then rinsed with TBST. The
primary antibody was a mouse monoclonal antibody
specific for influenza A nucleoprotein (NP) (F26NP9,
produced in-house) and was used at a 1:10,000 dilution
for one hour. They were then incubated for 15 minutes
with MM polymer-HRP (Biocare Medical, USA) and
reacted with the chromogen diaminobenzidine (DAB).
The sections were then counter stained with Gill’s
hematoxylin.
All animal experiments were performed with strict ad-
herence to the recommendations of the Canadian Coun-
cil on Animal Care (CCAC). The animal use document
was approved by the Animal Care Committee (AAC) of
the National Microbiology Laboratory, Canada.
Statistical analysis
Effects were evaluated by Wilcoxon’s Rank Sum test,
odds ratio (ORs) estimated by normal approximation for
small samples, and significance assessed by Fisher´s
exact method. Correlations were calculated with
Spearman’s Rho. Data analysis was conducted using R
statistical software, version 2.10.1. All tests were two
sided and not controlled for multiple comparisons.
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